These innovative companies are working to rapidly deliver better solutions to the world’s healthcare challenges.
ACTUS Biotechnologies: Convoy Therapeutics and EnduRx Pharmaceuticals (subsidiaries of ACTUS Biotechnologies)
Origin: Tucson AZ and San Diego, CA | Leadership: John Muraski, President
Focus: Therapeutics and Aesthetics
Convoy’s technology platform focuses on solving major unmet needs in aesthetics and pharmaceutical markets by creating novel topical
products that are more effective, safer and easier to use; EnduRx is developing therapeutics that specifically target diseased tissue, with the front-line program being focused on the development of a targeted nanosystem for the treatment of Glioblastoma Multiforme (GBM).
Origin: San Francisco, CA | Leadership: Arnon Rosenthal, CEO and Co-founder; Tillman Gerngross, Co-founder; Asa Abeliovich, Co-founder; Errik Anderson, Co-founder
Alector is dedicated to the discovery and development of novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders.
Amarantus BioScience Holdings, Inc.
Origin: San Francisco, CA | Leadership: Gerald E. Commissiong, President, CEO and Co-Founder
Focus: Therapeutics and Diagnostics
Amarantus BioScience Holdings, Inc. (“Amarantus”) is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis (programmed cell death).
Improves the therapeutic index of small molecule drugs by creating new chemical entities or therapeutic combinations with existing drugs.
Arcturus Therapeutics, Inc
Origin: San Diego, CA | Leadership: Joseph E. Payne, Founder and CEO; Pad Chivukula, Founder and CSO
Arcturus is poised to become an industry leader in RNAi technologies for the treatment of rare orphan diseases.
Origin: Bloomington, Indiana and San Francisco, CA │ Leadership: Founders: Uri Lopatin, CMO; Adam Zlotnick, CSO; William Turner, Head of Chemistry; Derek Small, Executive Chair; Richard Dimarchi, Director
Focus: Small Molecule Antivirals
Curative therapy for Hepatitis B
Bell Biosystems, Inc.
Origin: Menlo Park, CA │ Leadership: Dr. Caleb B. Bell III, Founder and Chief Executive Officer; Daniel Bell, Founder and Chief Financial Officer
Focus: Synthetic Biology
Bell Biosystems develops synthetic organelles to add new functions to cells; our first product, the Magnelle, creates a magnetic phenotype in labeled cells which enables in vivo tracking using MRI.
Clinical Metabolomics (ClinMet)
Origin: Redwood City, CA | Leadership: Yesh Subramanian, CEO
Focus: Diagnostics & Pharma Services
Clinical trial based metabolomics platform for pharma to improve drug efficacy, reduce drug toxicity and identify mechanistic pathways for personalized medicine.
Origin: San Diego, Ca | Leadership: Dinu Sen, CEO and Founder
Clinical development of therapeutic strategies that address currently unmet medical needs.
With a focus on brain tumors, we are in clinical development with highly potent oncolytic viruses to trigger anti tumor immunity.
Origin: Ann Arbor, MI | Leadership: Thomas Everist, Chairman
Focus: Personalized Medicine and Diagnostics
Develops and commercializes medically unique molecular and sensor based diagnostics, prognostics and therapeutic selection technologies for cancer and cardiovascular diseases, which help physicians improve medical outcomes and reduce the total cost of care.
Glycosensors and Diagnostics
Origin: Athens, GA | Leadership: Robert Woods, Founder & President; Lori Yang, Founder & CSO
Provides enabling technologies for applications in glycoscience
Hera Therapeutics Inc.
Origin: Del Mar, CA | Leadership: Karl Y Hostetler, CEO
Small molecule antivirals for unmet medical needs
Research and development of mechanism-based, proprietary biomarker and in vitro immunodiagnosis products for the early detection of protein amyloid diseases.
Origin: Los Angeles, CA | Leadership: Michel F. Levesque, Founder and Chairman
NeuroGeneration is a clinical stage biotechnology company with neural stem cell products targeting neurological disorders caused by cell loss or injury. It also identifies new targets for endogenous repair in the treatment of neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, Multiple Sclerosis, etc.
Design and develop novel small molecule compounds against a number of targets in the CNS targeting treatment-resistant depression, cognitive deficits in schizophrenia, symptomatic treatment of Parkinson's disease and developmental disorders such as Rett syndrome.
Origin: San Diego, CA | Leadership: Brian Spencer, Co-Founder & Chief Scientist; Mike Dunn, Co-Founder & CEO
NeuroTransit uses proprietary technology for the development of drug products that cross the blood-brain barrier (BBB) to treat neurologic, metabolic and oncologic diseases of the brain.
PHusis Therapeutics Inc.
Origin: Houston, TX | Leadership: Lynn Kirkpatrick, CEO
Focus: Novel small molecule therapeutics against critical oncology targets
PHusis is using novel approaches to more rapidly develop small molecule inhibitors of pleckstrin homology (PH) domain signaling proteins critical in a number of diseases including oncology, where current projects include inhibitors of AKT/PDPK1 signaling and oncogenic KRAS and NRAS.
Portable Genomics, Inc.
Origin: Bordeaux, France | Leadership: Patrick Merel, Founder and CEO
Focus: Wireless Genomics
Develops a mobile platform with a consumer-based approach to facilitate the understanding and use of genomic data linked with medical and lifestyle information, targeting pharma, healthcare and consumer markets.
Origin: San Diego, CA | Leadership: Helge Zieler, Founder and CEO
Focus: Renewable Fuels & Chemicals
Primordial Genetics is focused on developing genetic solutions for improvement of complex traits relating to product yield in microbes and higher organisms.
Origin: San Diego, CA | Leadership: Henry Pan, CEO
Focus: Biopharmaceutical/Clinical Diagnostics/Bioinformatics
Focused on improving trial outcomes by selecting the right patient cohort, thereby potentially improving drug efficacy in oncology, metabolic disorders, cardiovascular diseases, viral infections and immunological diseases.
Sialix is developing products based on new biological discoveries of non-human sialic acids, their dietary role and inflammatory consequences, and their potential impact on cancer, cardiovascular, and other inflammatory-mediated diseases.
Developing a first-in-class approach to treat acne and rejuvenate health and beauty of the skin based on the science of plasmonic resonance.
Origin: San Diego, CA | Leadership: Elisabeth Gardiner, CSO
Discovery and development of small molecule drugs that block inflammatory signaling in the brain. Our goal is provide life changing disease modifying therapeutics for cognitive impairment and brain injury.
Origin: Bologna, Italy | Leadership: Giusepp Giorgini, CEO
Proprietary lab-on-a-chip technology platform designed to individually identify, manipulate and sort specific cells within a heterogeneous population.
Origin: Busan, South Korea | Leadership: Co-CEOs: Yong-Han Lee and Eun-Sang Moon, Founder: Tae-Ho Hwang
A world-leading R&D company in immunotherapeutic oncolytic virus and viral gene therapies for critical unmet medical needs.
Live medical-grade video™ and high-resolution image capture from a patient’s mobile phone for clinician triage, remote diagnosis, follow-up care, drug compliance, and health status monitoring, all without the patient having to visit a brick-and-mortar medical facility.
Origin: Munich, Germany | Leadership: Robert Hillman
Medical diagnostic systems that provide a comprehensive profile of a patient's coagulation status.
Origin: San Francisco, CA | Leadership: Kimberlie Cerrone, Co-founder and CEO; Joydip Homchowdhury, Co-founder and Chief Product Officer
Focus: Digitial Health
Tiatros dramatically improves efficiency across the healthcare sector by connecting all of the people, clinical information, and real-time health data that is needed to support truly collaborative patient care, clinical research, and clinical trials inside a private, secure mobile cloud.
Origin: San Diego, CA | Leadership: Boris Markosian, Founder and CEO; Brandon Dolan, Director of scientific research; Daniel Dempsey, Director of operations; Thomas Ichim, CSO
Vaxenta focuses on the development and commercialization of safe, natural, and effective cancer therapies.
VLP Biotech, Inc
Origin: San Diego, CA | Leadership: Dave Milich, Founder & CEO; Yemi Onakunle, President
Developing safe, efficacious and cost effective vaccines based on our patented highly immunogenic virus-like-particle platform.
Origin: San Diego, CA | Leadership: Troy Wilson, President & CEO
Discovery and development of small molecule drugs that target signal transduction networks for the treatment of cancer and other diseases.
Whole Biome, Inc.
Origin: San Francisco, CA │ Leadership: Colleen Cutcliffe, Co-Founder, CEO; John Eid, Co-Founder, CSO; James Bullard, Co-Founder CTO
Whole Biome is ushering in a revolution in diagnostics and therapeutics where each individual's treatment will be driven by a comprehensive understanding and a targeted equilibration of their microbiome.
Origin: New Orleans, LA | Leadership: Aline M. Betancourt, Founder & CSO; Ruth S. Waterman, CEO
Develops uniform and predictable cell-based therapies for diseases associated with inflammation.
Origin: Mexico City, Mexico | Leadership: Alberto Osio, Founder & CEO
Focus: Medical Device
Non-invasive treatment to correct presbyopia using personalized contact lenses and specially formulated eye drops.
*Some companies have opted for non-disclosure and are therefore not included in this list.